SUMMARY
Lipotoxic cardiomyopathy (LCM) is characterized by abnormal myocardial
accumulation of lipids, including ceramide; however, the contribution of
ceramide to the etiology of LCM is unclear. Here, we investigated the
association of ceramide metabolism and ceramide-interacting proteins (CIPs) in
LCM in the Drosophila heart model. We find that ceramide
feeding or ceramide-elevating genetic manipulations are strongly associated with
cardiac dilation and defects in contractility. High ceramide-associated LCM is
prevented by inhibiting ceramide synthesis, establishing a robust model of
direct ceramide-associated LCM, corroborating previous indirect evidence in
mammals. We identified several CIPs from mouse heart and
Drosophila extracts, including caspase activator Annexin-X,
myosin chaperone Unc-45, and lipogenic enzyme FASN1, and remarkably, their
cardiac-specific manipulation can prevent LCM. Collectively, these data suggest
that high ceramide-associated lipotoxicity is mediated, in part, through
altering caspase activation, sarcomeric maintenance, and lipogenesis, thus
providing evidence for conserved mechanisms in LCM pathogenesis in mammals.